Momenta Pharmaceuticals, Inc. (MNTA)

[Rocky3]

• There could be some selling stemming from MNTA’s guidance for continued quarterly losses until Copaxone is approved, although this should not have been a surprise to anyone who follows the company closely.

I think that the guidance for a loss of $10-15MM per quarter (not the $50MM stated in the seekingalpha summary) may be higher than some thought would happen. In the past its guidance has been pretty good, but I have been burned so often by other company's low-ball estimates of burn that I will be using the high estimate, or slightly more, in my estimates. Clearly expenses are much higher now due to head-count, and going higher.

The emphasis on the Cop patents extending to the 3rd quarter of 2015 also was slightly different than most had understood (late 2014). So a possible delay in earnings is another issue from today.

The other news should have been known by those following the company. But as pointed out, investors tend to overact, at least in the short-term.

More opportunity to sell puts at 13 and 14.